CompletedNot Applicable

Recurrence and Bleeding in Colorectal Cancer Patients With Cancer-associated Venous Thrombembolism

China2,000 participantsStarted 2019-01-01

Plain-language summary

Patients with colorectal cancer (CRC) have a higher risk of both venous thromboembolism (VTE) and major bleeding (MB). Patients with CRC are underrepresented in the major trials examining treatment of cancer-associated VTE with anticoagulant.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Patients with histologically confirmed CRC and symptomatic or incidental VTE who received anticoagulant treatment.
. CRC patients with VTE treated with an anticoagulant (rivaroxaban or LMWH) for at least six months.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

recurrent VTE including deep vein thrombosis (DVT) and pulmonary embolism (PE)

Timeframe: From the date of index VTE to VTE recurrence, assessed up to 12 months

Major Bleeding (MB)

Timeframe: From the date of index VTE to MB occurrence, assessed up to 12 months

Clinical Relevant Non Major Bleeding (CRNMB)

Timeframe: From the date of index VTE to CRNMB occurrence, assessed up to 12 months

Trial details

NCT IDNCT06440044

SponsorSixth Affiliated Hospital, Sun Yat-sen University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-06-16

View on ClinicalTrials.gov More Thrombosis, Venous trials